LivaNova PLC $LIVN Shares Sold by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. lessened its position in shares of LivaNova PLC (NASDAQ:LIVN) by 59.9% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,531 shares of the company’s stock after selling 3,780 shares during the quarter. PNC Financial Services Group Inc.’s holdings in LivaNova were worth $99,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in LIVN. LSV Asset Management increased its stake in LivaNova by 278.3% during the first quarter. LSV Asset Management now owns 438,498 shares of the company’s stock worth $17,224,000 after acquiring an additional 322,598 shares during the last quarter. Seizert Capital Partners LLC purchased a new position in shares of LivaNova during the 1st quarter worth $3,896,000. Bayforest Capital Ltd acquired a new stake in shares of LivaNova during the 1st quarter worth about $590,000. XTX Topco Ltd purchased a new stake in LivaNova in the 1st quarter valued at about $557,000. Finally, GSA Capital Partners LLP raised its holdings in LivaNova by 313.3% in the 1st quarter. GSA Capital Partners LLP now owns 32,298 shares of the company’s stock valued at $1,269,000 after buying an additional 24,483 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Trading Down 0.2%

Shares of LIVN stock opened at $53.39 on Thursday. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $57.35. The company has a 50 day moving average price of $46.09 and a 200 day moving average price of $42.98. The stock has a market capitalization of $2.92 billion, a P/E ratio of -13.72 and a beta of 0.92. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.84 by $0.21. The company had revenue of $352.50 million for the quarter, compared to analyst estimates of $332.20 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The firm’s quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.93 EPS. Equities research analysts predict that LivaNova PLC will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on LIVN shares. Robert W. Baird increased their target price on shares of LivaNova from $55.00 to $61.00 and gave the stock an “outperform” rating in a research note on Thursday, May 8th. Wall Street Zen upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 9th. Barclays dropped their target price on shares of LivaNova from $56.00 to $55.00 and set an “equal weight” rating for the company in a report on Thursday, May 8th. Wolfe Research raised LivaNova from a “peer perform” rating to an “outperform” rating and set a $60.00 target price on the stock in a research report on Tuesday, May 20th. Finally, Needham & Company LLC restated a “buy” rating and set a $64.00 price target on shares of LivaNova in a research note on Tuesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $59.29.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.